Oncimmune “COVID-19 NavigAID panel participation enhances the investment case” says Zeus Capital

The award of funding to Oncimmune Holdings plc (LON:ONC) by the ‘UK Research and Innovation Ideas to Address COVID-19’ project, leverages its proprietary ImmunoINSIGHTS technology to help in predicting disease severity and treatment response, in collaboration with the Government’s research hub, Medicines Discovery Catapult (MDC). This is a strong signal of recognition, enables Oncimmune to participate in critical efforts to mitigate the pandemic, and further showcase its technology on a broad stage. The collaboration paves the way for deeper understanding of the role of immunity in COVID-19, and successful outcomes can result in Oncimmune’s ownership of differentiated proprietary assets with enormous medical value, and with broad commercial applications in COVID-19 drug and vaccine development.

The initial deliverable by Oncimmune, as part of its funded collaboration in the ‘Immunity Profiling of Patients with COVID-19 for Therapy and Triage’ (IMPACTT) programme with MDC, is a validated infectious disease (COVID-19) NavigAID™ biomarker panel; a prognostic tool, based on profiling the immune characteristics of 3,000 patient samples and clinical data, utilising its SeroTag™ platform. The resulting panel targets classification of symptoms as mild, moderate or severe, not only to help predict disease severity, but the likely responses to vaccines or therapies. In parallel, Oncimmune is building a specialised UK biorepository and data registry of COVID-19 samples, to deepen understanding of the disease and to support ongoing commercialisation of the ImmunoINSIGHTS platforms to the many biopharma companies seeking to tailor and optimise vaccines and therapies against the virus.

It is hugely impressive to see Oncimmune invited to participate in a high profile collaboration, motivated by its ‘pioneering technology’ as cited by UK Secretary of State for Business, Energy and Industrial Strategy. Oncimmune is working towards developing valuable, differentiated and wholly owned assets that can be subsequently commercialised to global biopharma, and anticipates that the panel will be ready for commercial roll out in around six months, and has generated significant interest already. With over 1,000 therapies and vaccines in development, once validated, a COVID-19 NavigAID™ panel can potentially help selective and tailored deployment of R&D resources and can be hugely valuable tool, likely to attract new revenue streams for Oncimmune.

Participation enhances the investment case for Oncimmune and provides another opportunity to validate its ImmunoINSIGHTS platform, signals the versatility of  technology and its potential applications not only for oncology and immune-related diseases, but also for infectious disease. This can build on existing strong momentum in its pipeline of contracted revenue with biopharma companies.

Click to view all articles for the EPIC: ,
Or click to view the full company profile:
    Facebook
    Twitter
    LinkedIn

    More articles like this

    AssetCo plc

    AssetCo performs better than forecasts says Zeus

    AssetCo plc (LON:ASTO) has just completed its acquisition of River and Mercantile Group “RMG”, which has resulted in an increase in shares in issue from 8.4m to 14.4m. RMG has an “established and well-respected equities team

    Tatton Asset Management Plc

    Tatton Asset Management meeting or beating Zeus forecasts

    Tatton Asset Management plc (LON:TAM) results to March 2022 are in line with its April trading update, confirming profitable growth with high retention. Headlines are: ¨ Assets under management (“AUM”) rose 26.1% to £11.34bn (2021: £8.99bn)

    Castings plc

    Castings Plc outlook underpinned by new platforms says Zeus

    Castings plc (LON:CGS) FY22 results show a marked recovery on the pandemic impacted FY21 numbers with volumes broadly in line with pre-Covid levels, albeit c.5% below FY19 peak. Revenue increased 29.5% to £148.6m (FY21: £114.7m) with

    OnTheMarket Plc

    OnTheMarket “delivering on expectations” says Zeus

    OnTheMarket plc (LON:OTMP) full year results to January 2022 are in line with the February trading update: ¨ 32% rise in revenue to £30.4m (FY21: £23.0m); ¨ 12% rise in Group adjusted operating profit to £2.7m

    DWF Group Plc

    DWF Group is significantly undervalued says Zeus

    DWF Group plc (LON:DWF) has announced it is on track to deliver our FY22 adjusted PBT forecast despite some challenges particularly on utilisation during H2. Lock up days also continue to fall, and we sense increasing

    Redde Northgate buy back own shares

    Redde Northgate plc (LON:REDD) have today announced that on the 5th May 2022 it purchased the following number of its own shares to be held in treasury: Class of shares :  Ordinary shares of 50p (“shares”) Number

    boohoo Plc

    boohoo group total group sales +61% since FY2020

    boohoo group plc (LON:BOO) have today published final results for the year ended 28th February 2022. Investing for the future ·    Significantly increased market share in the UK and US since FY2020. Total group sales +61% since FY2020 ·    Extended